Cleland Child
Internal Medicine · Honolulu, HINPI 1548242076
Payments from drug & device makers
Across 124 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$369
- Astellas Pharma US Inc$242
- AbbVie$171
- Novartis$155
- Johnson & Johnson$146
- GSK$130
- plus $789 from 19 others
What the payments were for
- Food & beverage$2,002100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $369 |
| Astellas Pharma US Inc | 15 | $242 |
| AbbVie | 9 | $171 |
| Novartis | 10 | $155 |
| Johnson & Johnson | 10 | $146 |
| GSK | 8 | $130 |
| AstraZeneca | 5 | $100 |
| Boehringer Ingelheim | 4 | $82 |
| Dexcom, Inc. | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| Pfizer | 4 | $61 |
| Amarin Pharma, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Amgen(2 entities) | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Lilly USA, LLC | 2 | $30 |
| Almatica Pharma LLC | 1 | $26 |
| Bayer | 1 | $23 |
| Abiomed | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Medtronic | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$2,002 in reported general payments places this provider in the 75th percentile of 655 internal medicine providers in Hawaii.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $19,053 |
| EliquisApixaban | 18 | $18,866 |
| BrilintaTicagrelor | 11 | $4,977 |
| Atorvastatin Calcium | 364 | $2,441 |
| Levothyroxine Sodium | 143 | $1,865 |
| Rosuvastatin Calcium | 76 | $1,416 |
| Nadolol | 18 | $1,328 |
| Amlodipine Besylate | 231 | $1,298 |
| SynthroidLevothyroxine Sodium | 12 | $1,252 |
| Omeprazole | 87 | $1,166 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,039 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 14 | $924 |
| Metoprolol Succinate | 61 | $868 |
| Gabapentin | 46 | $850 |
| Losartan Potassium | 73 | $792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $369 | $19,05317 claims |
| PfizerEliquis | $61 | $18,86618 claims |
| AstraZenecaBrilinta | $100 | $4,97711 claims |
| AbbVieSynthroid | $171 | $1,25212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Honolulu
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
- Anthony HernandezHonolulu$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.